Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of tumors from mice treated with FPC (5-FU, anti-PD-1 antibody, and anti-CTLA-4 antibody), mRNA–LNP and KDM5B inhibitors.

ABSTRACT: Chimeric antigen receptor (CAR) T cell therapy is a highly effective cancer treatment that harnesses immune cells. However, significant challenges remain, particularly with respect to its application to solid tumours and the high cost of manufacturing. To address these limitations, the development of mRNA–lipid nanoparticle (LNP) therapeutics capable of generating CAR-T cells in vivo has attracted increasing attention. In this study, we administered LNP-formulated mRNA encoding a fibroblast activation protein (FAP)-targeting CAR in a mouse tumour model and investigated how tumour-resident cells alter their gene expression profiles in response. We further examined how KDM5B inhibition influences the antitumor effect in combination with in vivo CAR-T therapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE319665 | GEO | 2026/07/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq of tumors from mice treated with FPC (5-FU, anti-PD-1 antibody, and anti-CTLA-4 antibody), mRNA–LNP and KDM5B inhibitors.

Project description:RNA-seq of tumors from mice treated with FPC (5-FU, anti-PD-1 antibody, and anti-CTLA-4 antibody), mRNA–LNP and KDM5B inhibitors.

| PRJNA1424926 | ENA

scRNA-seq of MC38 syngeneic colorectal tumors after FAP-CAR mRNA-LNP therapy

Project description:This study investigates the therapeutic potential of an mRNA–lipid nanoparticle (LNP)-based strategy delivering fibroblast activation protein (FAP)-specific chimeric antigen receptor (CAR) mRNA in colorectal cancer. Syngeneic colorectal mouse tumor models were treated with FAP-CAR mRNA-LNPs, and single-cell RNA sequencing (scRNA-seq) of tumor tissues was performed. The analysis aimed to explore mechanisms of tumor relapse following treatment, with a particular focus on the MIF–CD74 signaling axis. The data revealed heterogeneous immune and stromal cell states, highlighting immunosuppressive pathways associated with relapse.

2025-12-10 | GSE307699 | GEO

Multiomics analysis of naturally efficacious LNP coronas reveals high-density lipoprotein is necessary for LNP function. VLDLHDL corona

Project description:The MS data set contains the result from HDL VLDL corona used in the publication, titled Multiomics analysis of naturally efficacious LNP coronas reveals high-density lipoprotein is necessary for LNP function.

2023-06-07 | PXD041944 | Pride

Multiomics analysis of naturally efficacious LNP coronas reveals high-density lipoprotein is necessary for LNP function. Rat Plasma

Project description:The MS data set contains the result from each individual rat plasma used in the publication, titled Multiomics analysis of naturally efficacious LNP coronas reveals high-density lipoprotein is necessary for LNP function.

2023-06-07 | PXD041925 | Pride

Multiomics analysis of naturally efficacious LNP coronas reveals high-density lipoprotein is necessary for LNP function. Individual corona

Project description:The MS data set contains the result from each individual rat plasma derived corona used in the publication, titled Multiomics analysis of naturally efficacious LNP coronas reveals high-density lipoprotein is necessary for LNP function.

2023-06-07 | PXD041938 | Pride

RNA-seq of colorectal cancer patient-derived xenograft (PDX) tumors treated with FAP-CAR mRNA-LNP therapy

Project description:This study investigates the therapeutic potential of an mRNA–lipid nanoparticle (LNP)-based strategy to deliver fibroblast activation protein (FAP)-specific chimeric antigen receptor (CAR) mRNA in colorectal cancer. Patient-derived xenograft (PDX) tumor models (PDX-1 and PDX-2) were treated by splenocytes with FAP-CAR mRNA-LNPs, including wild-type or 7SL1 knock-in splenocytes, in comparison with PBS controls. RNA sequencing of the tumor tissues was performed to profile transcriptional responses associated with treatment efficacy or resistance. Differential expression and pathway enrichment analyses revealed distinct immune and stromal gene programs, including HOX family transcription factor activation in resistant tumors.

2025-12-10 | GSE307698 | GEO

ATAC-seq of colorectal cancer patient-derived xenograft (PDX) tumors treated with FAP-CAR mRNA-LNP therapy

Project description:This study investigates the therapeutic potential of an mRNA–lipid nanoparticle (LNP)-based strategy to deliver fibroblast activation protein (FAP)-specific chimeric antigen receptor (CAR) mRNA in colorectal cancer. Patient-derived xenograft (PDX) tumor models (PDX-1 and PDX-2) were treated by splenocytes (7SL1 knock-in) with FAP-CAR mRNA-LNPs, in comparison with PBS controls. ATAC sequencing of the tumor tissues was performed to profile transcriptional responses associated with treatment efficacy or resistance. Analysis revealed distinct chromatin accessibility programs, including activation of HOX gene clusters in resistant tumors, highlighting potential epigenetic mechanisms of therapeutic escape.

2025-12-10 | GSE307697 | GEO

Targeting the Cancer-Retina Antigen PDE6G with mRNA-LNP Vaccine Elicits Potent Anti-Tumor Immunity Against Breast Cancer

Project description:The development of effective mRNA vaccines for breast cancer has been constrained by the lack of highly immunogenic and tumor-specific antigens. Here, we identify PDE6G, an immune-privileged retina-enriched antigen aberrantly overexpressed in breast tumors, and develop a PDE6G mRNA-LNP vaccine. Vaccination elicited robust CD8+ T cell responses, promoted clonal expansion of effector and IFN-competent T cell subsets, and suppressed tumor growth without detectable toxicity. Single-cell RNA sequencing (scRNA-seq) revealed that vaccination of PDE6G mRNA-LNP reshapes the tumor immune microenvironment (TIME) by expanding antigen-presenting Cd74+ tumor-associated macrophages (TAMs) while reducing immunosuppressive Maf+ macrophages, and enhancing crosstalk between macrophages and CD8+ T cells. Moreover, combining PDE6G mRNA-LNP with PD-1 blockade further improved anti-tumor efficacy. These findings establish cancer-retina antigens as promising vaccine targets and demonstrate that PDE6G mRNA-LNP coordinates adaptive immunity and tumor microenvironment remodeling, providing a safe and potent strategy for breast cancer immunotherapy.

2026-01-30 | GSE317984 | GEO

A quadrivalent in vivo CAR-macrophage repress solid tumors and overcome tumor heterogeneity through antigen spreading

Project description:We designed a quadrivalent in vivo CAR-engineered macrophage based on the LNP-mRNA system, delivering FAP CAR-ΔTGFβRII and GPC3 CAR-Super IL2 (LNP-GF CAR) via LNP for the treatment of primary hepatocellular carcinoma. LNP-GF CAR demonstrated significant anti-tumor efficacy in a primary hepatocellular carcinoma mouse model. To further dissect the anti-tumor mechanism of LNP-GF CAR, we performed single-cell transcriptomic sequencing on tumor regions of the liver from treated model mice. Based on the single-cell transcriptomic data, we found that exogenous CAR mRNA was highly enriched in tissue-resident macrophages within the liver tumor regions. CAR-expressing macrophages showed significant upregulation of genes related to antigen cross-presentation and promotion of T cell activation and proliferation. Consistently, the numbers of proliferative and activated CD8 T cells were significantly increased. These findings provide further evidence that in situ CAR macrophages can activate CD8 T cells through antigen cross-presentation, and deepen our understanding of the anti-tumor mechanism of LNP-GF CAR.

2026-05-16 | GSE330648 | GEO

Prototype LNP-mRNA vaccine candidates [SC_RNAseq]

Project description:We developed prototype LNP-mRNA vaccine candidates against SARS-CoV-2 Delta, SARS-CoV and MERS-CoV, and test how multiplexing LNP-mRNAs can induce effective immune responses in animal models. Triplex and Duplex LNP-mRNA vaccination induced antigen-specific antibody responses against SARS-CoV-2, SARS-CoV and MERS-CoV. Single cell RNA-seq profiled the global systemic immune repertoires and respective transcriptome signatures of vaccinated animals, revealing systemic increase in activated B cells, and differential gene expression across major adaptive immune cells. Sequential vaccination showed potent antibody responses against all three species, significantly stronger than simultaneous vaccination in mixture. These data demonstrated feasibility, antibody responses and single cell immune profiles of multi-species coronavirus vaccination. The direct comparison between simultaneous and sequential vaccination offers insights on optimization of vaccination schedules to provide broad and potent antibody immunity against three major pathogenic coronavirus species.

2025-07-30 | GSE207141 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data